These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 25184810)

  • 1. Bioorthogonal labeling and profiling of N6-isopentenyladenosine (i6A) modified RNA.
    Li Y; Zhou H; Chen S; Li Y; Guo Y; Chen X; Wang S; Wang L; Gan Y; Zhang S; Zheng YY; Sheng J; Zhou Z; Wang R
    Nucleic Acids Res; 2024 Apr; 52(6):2808-2820. PubMed ID: 38426933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the investigation of N
    Lin XN; Gai BX; Liu L; Cheng L
    Bioorg Med Chem; 2024 Aug; 110():117838. PubMed ID: 39018794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MODOMICS: a database of RNA modification pathways. 2017 update.
    Boccaletto P; Machnicka MA; Purta E; Piatkowski P; Baginski B; Wirecki TK; de Crécy-Lagard V; Ross R; Limbach PA; Kotter A; Helm M; Bujnicki JM
    Nucleic Acids Res; 2018 Jan; 46(D1):D303-D307. PubMed ID: 29106616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of the biosynthesis pathway for threonylcarbamoyladenosine (t(6)A), a universal modification of tRNA.
    Thiaville PC; Iwata-Reuyl D; de Crécy-Lagard V
    RNA Biol; 2014; 11(12):1529-39. PubMed ID: 25629598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases.
    Proto MC; Fiore D; Piscopo C; Laezza C; Bifulco M; Gazzerro P
    Front Pharmacol; 2022; 13():815646. PubMed ID: 35559231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards an Improvement of Anticancer Activity of Benzyl Adenosine Analogs.
    Covelli V; Grimaldi M; Randino R; Firoznezhad M; Proto MC; Simone V; Matteoli G; Gazzerro P; Bifulco M; D'Ursi AM; Rodriquez M
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting prenylation inhibition through the mevalonate pathway.
    Manaswiyoungkul P; de Araujo ED; Gunning PT
    RSC Med Chem; 2020 Jan; 11(1):51-71. PubMed ID: 33479604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition?
    Dulińska-Litewka J; Gąsiorkiewicz B; Litewka A; Gil D; Gołąbek T; Okoń K
    Med Oncol; 2020 Feb; 37(3):17. PubMed ID: 32030542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N
    Navarra G; Pagano C; Pacelli R; Crescenzi E; Longobardi E; Gazzerro P; Fiore D; Pastorino O; Pentimalli F; Laezza C; Bifulco M
    Front Oncol; 2019; 9():1498. PubMed ID: 31993371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.
    Fiore D; Piscopo C; Proto MC; Vasaturo M; Dal Piaz F; Fusco BM; Pagano C; Laezza C; Bifulco M; Gazzerro P
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.
    Ranieri R; Ciaglia E; Amodio G; Picardi P; Proto MC; Gazzerro P; Laezza C; Remondelli P; Bifulco M; Pisanti S
    Cell Death Differ; 2018 Feb; 25(2):353-367. PubMed ID: 29027991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.
    Proto MC; Fiore D; Piscopo C; Franceschelli S; Bizzarro V; Laezza C; Lauro G; Feoli A; Tosco A; Bifulco G; Sbardella G; Bifulco M; Gazzerro P
    Sci Rep; 2017 Sep; 7(1):11678. PubMed ID: 28916833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural evidence of N6-isopentenyladenosine as a new ligand of farnesyl pyrophosphate synthase.
    Scrima M; Lauro G; Grimaldi M; Di Marino S; Tosco A; Picardi P; Gazzerro P; Riccio R; Novellino E; Bifulco M; Bifulco G; D'Ursi AM
    J Med Chem; 2014 Sep; 57(18):7798-803. PubMed ID: 25184810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity.
    Grimaldi M; Randino R; Ciaglia E; Scrima M; Buonocore M; Stillitano I; Abate M; Covelli V; Tosco A; Gazzerro P; Bifulco M; Rodriquez M; D'Ursi AM
    Bioorg Chem; 2020 May; 98():103449. PubMed ID: 32057422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation.
    Laezza C; Notarnicola M; Caruso MG; Messa C; Macchia M; Bertini S; Minutolo F; Portella G; Fiorentino L; Stingo S; Bifulco M
    FASEB J; 2006 Mar; 20(3):412-8. PubMed ID: 16507758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The isoprenoid derivative N
    Ciaglia E; Grimaldi M; Abate M; Scrima M; Rodriquez M; Laezza C; Ranieri R; Pisanti S; Ciuffreda P; Manera C; Gazzerro P; D'Ursi AM; Bifulco M
    Br J Pharmacol; 2017 Jul; 174(14):2287-2301. PubMed ID: 28419419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological and pharmacological roles of N6-isopentenyladenosine: an emerging anticancer drug.
    Bifulco M; Malfitano AM; Proto MC; Santoro A; Caruso MG; Laezza C
    Anticancer Agents Med Chem; 2008 Feb; 8(2):200-4. PubMed ID: 18288922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase.
    Ohno K; Mori K; Orita M; Takeuchi M
    Curr Med Chem; 2011; 18(2):220-33. PubMed ID: 21110804
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.